Marko Hojnik (Author), Nataša Kenda Šuster (Author), Špela Smrkolj (Author), Damjan Sisinger (Author), Snježana Frković-Grazio (Author), Ivan Verdenik (Author), Tea Lanišnik-Rižner (Author)

Abstract

Although aldo-keto reductases (AKRs) have been widely studied in cancer, no study to date has examined the roles of AKR family 1 members B1 (AKR1B1) and B10 (AKR1B10) in a large group of ovarian cancer patients. AKR1B1 and AKR1B10 play a significant role in inflammation and the metabolism of different chemotherapeutics as well as cell differentiation, proliferation, and apoptosis. Due to these functions, we examined the potential of AKR1B1 and AKR1B10 as tissue biomarkers. We assessed the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 99 patients with high-grade serous ovarian cancer (HGSC) and compared these levels with clinicopathological characteristics, survival, and response to chemotherapy. A higher immunohistochemical AKR1B1 expression correlated with a better overall and disease-free survival of HGSC patients whereas AKR1B10 expression did not show any significant differences. A multivariant Cox analysis demonstrated that a high AKR1B1 expression was an important prognostic factor for both overall and disease-free survival. However, AKR1B1 and AKR1B10 were not associated with different responses to chemotherapy. Our data suggest that AKR1B1 is involved in the pathogenesis of HGSC and is a potential prognostic biomarker for this cancer.

Keywords

high-grade serous ovarian cancer;immunohistochemistry;survival;

Data

Language: English
Year of publishing:
Typology: 1.01 - Original Scientific Article
Organization: UL MF - Faculty of Medicine
UDC: 618.1
COBISS: 96813059 Link will open in a new window
ISSN: 2072-6694
Views: 73
Downloads: 32
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: serozni rak jajčnikov visoke stopnje;imunohistokemija;preživetje;
Type (COBISS): Article
Pages: str. 1-15
Volume: ǂVol. ǂ14
Issue: ǂiss. ǂ3
Chronology: 2022
DOI: 10.3390/cancers14030809
ID: 15624568